Prospects for using orthobiologic products in knee osteoarthritis: а review
- 21 December 2025
- journal article
- Published by ECO-Vector LLC (Publications) in N.N. Priorov Journal of Traumatology and Orthopedics
- Vol. 33 (1) , 220-239
Abstract
Osteoarthritis is the most common joint disease, causing damage to cartilage and surrounding tissues and potentially leading to varying degrees of disability. The disease is characterized by pain, stiffness, and loss of function. Osteoarthritis is classified as primary and secondary. The cause of primary (or idiopathic) osteoarthritis is unknown (primary osteoarthritis accounts for the vast majority of cases). Secondary osteoarthritis may be caused by another disease or disorder, such as infection, congenital joint malformation, trauma, metabolic disorders, rheumatoid arthritis, and others. The main goals of treatment include relief of pain, preservation of joint flexibility, and optimization of joint function. Currently used conservative treatment methods are mainly aimed at reducing pain and improving the patient’s quality of life; however, they do not eliminate the underlying cause of the disease and, accordingly, are not capable of completely halting the degradation of hyaline cartilage. Attempts at joint-preserving surgery in cases of involvement of one of the knee joint compartments, such as corrective osteotomy, can significantly improve treatment outcomes but tend to delay rather than prevent the need for joint arthroplasty. Therefore, the development of treatment methods that enable joint preservation and restoration of cartilage and subchondral bone defects remains highly relevant. At present, the search for such methods is focused on the use of orthobiologic products. This article addresses the application of these approaches in the treatment of knee joint conditions. A detailed description of the composition and mechanisms of action of two orthobiologic products of greatest interest to practicing clinicians—platelet-rich plasma and stromal vascular fraction—is presented. The results of preclinical and clinical studies demonstrating the ability of these products to reduce inflammation, alleviate pain, and remarkably improve the function of the affected joint are provided. Thus, scientific studies confirm the therapeutic efficacy of orthobiologic products, the use of which opens new prospects for joint-preserving treatment of patients with osteoarthritis.Keywords
This publication has 146 references indexed in Scilit:
- Regenerative Medicine Applications of Mesenchymal Stem Cells2018
- Intra‐articular injection of autologous adipose‐derived mesenchymal stem cells in the treatment of knee osteoarthritisThe Journal of Gene Medicine, 2018
- Intra‐Articular Injection of Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee: A Proof‐of‐Concept Clinical TrialStem Cells, 2014
- Previously Reported Prior Studies of Cherry Juice Concentrate for Gout Flare Prophylaxis: Comment on the Article by Zhang et alArthritis & Rheumatism, 2013
- Antiinflammatory and chondroprotective effects of intraarticular injection of adipose‐derived stem cells in experimental osteoarthritisArthritis & Rheumatism, 2012
- Intraarticular injection of platelet‐rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee jointArthritis & Rheumatism, 2011
- Autologous protein solution inhibits MMP‐13 production by IL‐1β and TNFα‐stimulated human articular chondrocytesJournal of Orthopaedic Research, 2011
- Molecular basis of anti‐inflammatory action of platelet‐rich plasma on human chondrocytes: Mechanisms of NF‐κB inhibition via HGFJournal of Cellular Physiology, 2010
- Platelet‐rich plasma: intra‐articular knee injections produced favorable results on degenerative cartilage lesionsKnee Surgery, Sports Traumatology, Arthroscopy, 2009
- Stem cell therapy in a caprine model of osteoarthritisArthritis & Rheumatism, 2003